The effect of nasal decongestion on nasal patency and nasalance scores in subjects with normal speech.
OBJECTIVE
The objective of this study was to evaluate the effects of pharmacological decongestion on nasalance scores.


METHODS
The participants were 20 adults with normal speech and resonance.


METHODS
Nasal patency was first determined by measuring the mean minimal cross-sectional area of the nasal passages by acoustic rhinometry. Each participant then read two passages as two predecongestion nasalance scores were obtained. A nasal decongestant was then administered to each nostril without removing the separation plate. Ten minutes later, nasalance scores were repeated. Finally, the separation plate was removed and the mean minimal cross-sectional area was obtained again.


METHODS
The outcome measures were the pre- and postdecongestion measurements of nasal patency and nasalance scores.


RESULTS
Minimal cross-sectional area increased significantly from 0.53 cm(2) before decongestion to 0.66 cm(2) after decongestion. For the Turtle Passage, the group mean nasalance for the two predecongestion measures (10.70% versus 11.55%) were significantly different and the pre- versus postdecongestion measures (10.70% versus 12.15%) were also significantly different. For the Mouse Passage, the group mean nasalance scores for the two predecongestion measures (32.10% versus 32.00%) were not significantly different but the pre- versus postdecongestion means (32.10 versus 34.40) were significantly different. Correlation coefficients showed a negligible relationship between measures of nasal patency and nasalance scores for both stimulus passages.


CONCLUSIONS
Nasalance score variability was small and not meaningful for standard clinical purposes. The correlation between nasalance scores and nasal patency was weak.
Watterson
Thomas
T
University of Nevada School of Medicine, Reno, Nevada 89557, USA.
Lewis
Kerry E
KE
Ludlow
Jennifer C
JC
Ludlow
Paul C
PC
D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014663:Nasal Decongestants / Q000008:administration & dosage*; D015508:Nasal Obstruction / Q000188:drug therapy*; D009666:Nose / Q000033:anatomy & histology; D012123:Pulmonary Ventilation / Q000187:drug effects; D023842:Rhinometry, Acoustic; D013068:Speech Production Measurement / Q000379:methods; D014833:Voice Quality / Q000187:drug effects*; D055815:Young Adult
D014663:Nasal Decongestants